ATE368221T1 - Immunoassays für anti-hcv-antikörper - Google Patents

Immunoassays für anti-hcv-antikörper

Info

Publication number
ATE368221T1
ATE368221T1 AT01952156T AT01952156T ATE368221T1 AT E368221 T1 ATE368221 T1 AT E368221T1 AT 01952156 T AT01952156 T AT 01952156T AT 01952156 T AT01952156 T AT 01952156T AT E368221 T1 ATE368221 T1 AT E368221T1
Authority
AT
Austria
Prior art keywords
hcv
antigens
multiple epitope
epitope fusion
immunoassays
Prior art date
Application number
AT01952156T
Other languages
English (en)
Inventor
David Chien
Phillip Arcangel
Laura Tandeske
Carlos George-Nasciemento
Doris Coit
Angelica Medina-Selby
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27395684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE368221(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE368221T1 publication Critical patent/ATE368221T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01952156T 2000-06-15 2001-06-14 Immunoassays für anti-hcv-antikörper ATE368221T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21208200P 2000-06-15 2000-06-15
US28081101P 2001-04-02 2001-04-02
US28086701P 2001-04-02 2001-04-02

Publications (1)

Publication Number Publication Date
ATE368221T1 true ATE368221T1 (de) 2007-08-15

Family

ID=27395684

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01952156T ATE368221T1 (de) 2000-06-15 2001-06-14 Immunoassays für anti-hcv-antikörper
AT01952160T ATE348337T1 (de) 2000-06-15 2001-06-14 Hcv-antigen/antikörper-kombinations-assay

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01952160T ATE348337T1 (de) 2000-06-15 2001-06-14 Hcv-antigen/antikörper-kombinations-assay

Country Status (22)

Country Link
US (5) US6632601B2 (de)
EP (2) EP1350105B1 (de)
JP (3) JP4834279B2 (de)
CN (3) CN1214244C (de)
AT (2) ATE368221T1 (de)
AU (2) AU2001272948A1 (de)
BG (1) BG66205B1 (de)
BR (2) BRPI0111731C1 (de)
CA (2) CA2412035C (de)
CY (2) CY1107537T1 (de)
CZ (1) CZ304185B6 (de)
DE (2) DE60125240T3 (de)
DK (2) DK1350105T3 (de)
ES (2) ES2277932T5 (de)
HU (1) HU228873B1 (de)
MX (2) MXPA02012424A (de)
NO (1) NO332275B1 (de)
PL (1) PL213363B1 (de)
PT (2) PT1354204E (de)
SI (1) SI1354204T2 (de)
SK (1) SK287694B6 (de)
WO (2) WO2001096870A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433160T2 (de) * 1993-05-12 2004-07-08 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
US7491808B2 (en) * 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
SK287694B6 (sk) * 2000-06-15 2011-06-06 Novartis Vaccines & Diagnostics, Inc. Pevný nosič imunoeseje a spôsob jeho prípravy, spôsob detekcie infekcie HIV a súprava na imunodiagnostickú skúšku
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU2001292151B2 (en) * 2000-08-17 2006-05-04 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
DE10106295C1 (de) * 2001-02-02 2002-08-22 Gaifar German American Inst Fo Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist
AU785380B2 (en) * 2001-03-28 2007-03-15 Ortho-Clinical Diagnostics, Inc. A hepatitis C antigen - antibody combination assay for the early detection of HCV infection
US7101683B2 (en) * 2001-06-26 2006-09-05 Abbott Laboratories Methods for the simultaneous detection of HCV antigens and HCV antibodies
JP4353793B2 (ja) 2001-06-26 2009-10-28 アボット・ラボラトリーズ Ｈｃｖ抗原とｈｃｖ抗体との同時検出のための方法
US7049060B2 (en) * 2001-11-05 2006-05-23 Ortho-Clinical Diagnostics, Inc. HCV anti-core monoclonal antibodies
US7332269B2 (en) * 2001-11-11 2008-02-19 Ortho-Clinical Diagnostics, Inc. HCV core protein sequences
FR2839555B1 (fr) 2002-05-10 2007-07-27 Bio Rad Pasteur Procede de detection simultanee d'un antigene et d'un anticorps d'un microorganisme infectieux
US7166426B2 (en) * 2002-09-09 2007-01-23 Novartis Vaccines And Diagnostics, Inc. HCV assay
US20040152070A1 (en) * 2003-02-04 2004-08-05 Shah Dinesh O. Method of detection of HCV antibodies in combination assay or sole antibody assay
EP1668369B1 (de) 2003-08-20 2016-01-06 ProMIS Neurosciences Inc. Epitopschutztest und verfahren zum nachweis von proteinkonformationen
ATE542140T1 (de) * 2004-08-27 2012-02-15 Novartis Vaccines & Diagnostic Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür
WO2006081701A1 (fr) * 2005-02-02 2006-08-10 Peng Cui Kit de detection de l'anticorps du vhc et procede de preparation de celui-ci
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
US7794692B2 (en) * 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
DK2514823T3 (en) 2006-03-03 2018-07-23 Promis Neurosciences Inc Methods and compositions for treating and detecting failed SOD1-mediated diseases
CN1908666B (zh) * 2006-08-14 2010-05-12 武汉大学 一种检测乙肝核心抗体的双夹心法酶联免疫诊断试剂盒及应用
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2010112733A1 (fr) * 2009-03-30 2010-10-07 bioMérieux Support solide de détection du vhc
US20100297607A1 (en) * 2009-05-20 2010-11-25 Jian Zheng Reagents For HCV Antigen-Antibody Combination Assays
JP2013529894A (ja) 2010-04-07 2013-07-25 ノバルティス アーゲー パルボウイルスｂ１９のウイルス様粒子を生成するための方法
CN102947703A (zh) * 2010-06-17 2013-02-27 皇家飞利浦电子股份有限公司 多表位测定
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
WO2012006500A2 (en) * 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
BR112013017961A2 (pt) * 2011-01-13 2017-07-25 Ortho Clinical Diagnostics Inc antígeno tripleto para treponema pallidum
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
EP2970947A4 (de) 2013-03-14 2016-10-12 Abbott Lab Rekombinante hcv-ns3-antigene und mutanten für den verbesserten nachweis von antikörpern
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
CN103630690B (zh) * 2013-12-17 2014-08-20 朱之炜 丙型肝炎病毒抗原抗体联合检测试剂盒及其检测方法
EP3274478B1 (de) 2015-03-27 2020-09-23 Ortho-Clinical Diagnostics, Inc. Hcv-ns4a/modifizierte ns3-polypeptide und verwendungen davon
WO2016172121A1 (en) * 2015-04-20 2016-10-27 Qoolabs, Inc. Camelid single-domain hcv antibodies and methods of use
EP3688185B1 (de) * 2017-09-27 2023-01-18 Bio-Rad Laboratories, Inc. Test für digitale affinitätsverknüpfung
CN110261616B (zh) * 2019-04-30 2021-07-20 广东菲鹏生物有限公司 一种丙型肝炎病毒检测试剂盒
CN115057943B (zh) * 2022-06-22 2025-03-14 杭州水芭莎生物医药科技有限公司 一种抗菌肽融合蛋白及其制备方法和应用
CN115838420B (zh) * 2022-10-31 2023-05-05 北京科跃中楷生物技术有限公司 一种可溶性hcv重组蛋白的制备方法及其制备的抗体检测试剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2212511B (en) * 1987-11-18 1992-01-22 Chiron Corp Hepatitis c virus
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
BR8807310A (pt) * 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
JP2730153B2 (ja) 1989-03-16 1998-03-25 日本合成ゴム株式会社 熱可塑性樹脂組成物およびその製造方法
HU225068B1 (en) 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
JP2656996B2 (ja) * 1989-05-18 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
US5712087A (en) 1990-04-04 1998-01-27 Chiron Corporation Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
WO1991015771A1 (en) * 1990-04-04 1991-10-17 Chiron Corporation Combinations of hepatitis c virus (hcv) antigens for use in immunoassays for anti-hcv antibodies
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
PT97247B (pt) * 1991-04-03 1997-10-31 Chiron Corp Processo de preparacao de combinacoes de antigenios do virus da hepapite c (hcv) para uso em imunoensaios para anticorpos anti-hcv
KR0185426B1 (ko) 1991-06-24 1999-04-01 로버트 피. 블랙버언 씨형 간염 바이러스 폴리펩티드
UA39944C2 (uk) 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
ATE551423T1 (de) * 1993-04-27 2012-04-15 Innogenetics Nv Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
JP3217600B2 (ja) 1994-07-12 2001-10-09 株式会社先端生命科学研究所 非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
US5843752A (en) 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US6514731B1 (en) * 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
JP3945822B2 (ja) 1996-05-24 2007-07-18 カイロン コーポレイション 複数エピトープ融合タンパク質
EP0870830A3 (de) * 1997-02-10 2004-02-25 Advanced Life Science Institute, Inc. Chimäres Hepatitis C-Virusantigen
PT1021719E (pt) * 1997-09-22 2007-03-30 Novartis Vaccines & Diagnostic Método para detecção de anticorpos numa amostra
JP3514729B2 (ja) * 1998-07-30 2004-03-31 株式会社先端生命科学研究所 Ｃ型肝炎ウイルスの測定方法
SK287694B6 (sk) * 2000-06-15 2011-06-06 Novartis Vaccines & Diagnostics, Inc. Pevný nosič imunoeseje a spôsob jeho prípravy, spôsob detekcie infekcie HIV a súprava na imunodiagnostickú skúšku

Also Published As

Publication number Publication date
BR0111682A (pt) 2004-01-06
ES2277932T3 (es) 2007-08-01
CY1107537T1 (el) 2013-03-13
AU2001272945A1 (en) 2001-12-24
JP2004506878A (ja) 2004-03-04
HK1061861A1 (en) 2004-10-08
CA2412035C (en) 2012-04-10
CZ304185B6 (cs) 2013-12-11
WO2001096875A3 (en) 2003-08-28
MXPA02012424A (es) 2003-04-25
NO20025878D0 (no) 2002-12-06
AU2001272948A1 (en) 2001-12-24
US6797809B2 (en) 2004-09-28
SK287694B6 (sk) 2011-06-06
CN1660913A (zh) 2005-08-31
HK1079796A1 (en) 2006-04-13
US20040063092A1 (en) 2004-04-01
EP1354204B1 (de) 2006-12-13
CN1214244C (zh) 2005-08-10
WO2001096870A2 (en) 2001-12-20
EP1350105A2 (de) 2003-10-08
DE60129598T2 (de) 2008-04-17
CN100463922C (zh) 2009-02-25
WO2001096875A9 (en) 2002-08-15
US20020192639A1 (en) 2002-12-19
DE60129598D1 (de) 2007-09-06
US7241879B2 (en) 2007-07-10
US7319144B2 (en) 2008-01-15
CZ20024058A3 (cs) 2003-09-17
BRPI0111731C1 (pt) 2021-07-27
ES2277932T5 (es) 2010-06-28
BRPI0111731B8 (pt) 2016-08-23
CA2412035A1 (en) 2001-12-20
CN1256591C (zh) 2006-05-17
WO2001096875A2 (en) 2001-12-20
BG107441A (bg) 2004-01-30
BRPI0111682B1 (pt) 2017-09-19
PL365599A1 (en) 2005-01-10
CA2413003A1 (en) 2001-12-20
US20040096822A1 (en) 2004-05-20
NO332275B1 (no) 2012-08-13
PT1354204E (pt) 2007-03-30
US20020146685A1 (en) 2002-10-10
SI1354204T2 (sl) 2010-09-30
US6632601B2 (en) 2003-10-14
BRPI0111731B1 (pt) 2016-07-05
HUP0500444A3 (en) 2010-03-29
BR0111731A (pt) 2004-02-10
MXPA02012401A (es) 2003-04-25
NO20025878L (no) 2003-02-12
DE60125240T2 (de) 2007-07-12
CA2413003C (en) 2013-08-13
PT1350105E (pt) 2007-08-13
BG66205B1 (bg) 2012-01-31
JP2011125350A (ja) 2011-06-30
DE60125240T3 (de) 2010-10-28
DK1354204T4 (da) 2010-06-14
BRPI0111682B8 (pt) 2021-07-27
DK1350105T3 (da) 2007-11-12
WO2001096870A3 (en) 2003-07-31
DE60125240D1 (de) 2007-01-25
JP2004510133A (ja) 2004-04-02
SK17772002A3 (sk) 2003-10-07
US20040265801A1 (en) 2004-12-30
CN1489692A (zh) 2004-04-14
EP1350105B1 (de) 2007-07-25
EP1354204B2 (de) 2010-04-21
CY1106820T1 (el) 2012-05-23
HU228873B1 (hu) 2013-06-28
JP4834279B2 (ja) 2011-12-14
CN1466682A (zh) 2004-01-07
DK1354204T3 (da) 2007-04-10
US6630298B2 (en) 2003-10-07
PL213363B1 (pl) 2013-02-28
EP1354204A2 (de) 2003-10-22
JP4837229B2 (ja) 2011-12-14
ATE348337T1 (de) 2007-01-15
ES2288969T3 (es) 2008-02-01
HUP0500444A2 (hu) 2005-08-29
SI1354204T1 (sl) 2007-04-30

Similar Documents

Publication Publication Date Title
DE60129598D1 (de) Immunoassays für anti-hcv-antikörper
WO2002090961A3 (en) Systems and methods for detection of analytes in biological fluids
US6723502B2 (en) Hepatitis C antigen—antibody combination assay for the early detection of infection
ATE410693T1 (de) Hcv-test
KR930008155A (ko) 씨형 간염 바이러스(hcv)에 대한 모노클로날 항체
EP1310796A3 (de) Reagenzien zum gleichzeitigen Nachweis von HCV-Kernantigenen und -Antikörpern
DK1257823T3 (da) Fremgangsmåde til påvisning af Helicobacter pylori og heilmanii
CA2380777A1 (en) Hepatitis c viral antigen immunoassay detection systems
ATE295375T1 (de) Antikörper und sonstige bindungsmoleküle gegen hepatitis b virusantigene
JP4283527B2 (ja) Ｈｃｖコア・タンパク質配列
Ireland Development of enzyme-linked immunosorbent assays for antibodies to hepatitis B virus.
TH40142A (th) การทดสอบภูมิคุ้มกันสำหรับโปรคอลลาเจน -iii-c- เทอร์มินัล
Rivanera et al. Evaluation of indeterminate sera for hepatitis C virus by assays using synthetic peptides
AR037215A1 (es) Reactivos para la deteccion simultanea de anticuerpos y antigenos nucleares del hcv
AU2007200598A1 (en) A hepatitis C antigen - antibody combination assay for the early detection of HCV infection
RU2000130737A (ru) Иммунодиагностикум рака яичников и способ его получения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1350105

Country of ref document: EP